2023 Revision to USP 797: What Home Infusion Pharmacies Need to Know - INFUSION Article

On November 1, 2022 USP released the revised version of General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, which becomes enforceable November 1, 2023. Although revisions were proposed (and subsequently appealed) in previous years, this version will represent a significant change from the 2008 standards which are currently enforceable. Home infusion pharmacists, pharmacy technicians, nurses, and dietitians will need to comprehend how the updated standards apply to their sterile compounding operations. This article will cover the significant areas, including: beyond-use dating for categories 1, 2, and 3 CSPs, requirements for clean room personnel qualification and evaluation, the need for a designated person(s) to ensure the sterile environment maintains quality, environmental monitoring changes and the need for increased testing and cleaning.

Learning Objectives:

  1. Review the latest updates to USP General Chapter <797> compared to the 2008 version which remains enforceable until November 1, 2023. 
  2. Understand the difference between Category 1, 2, and 3 compounded sterile preparations (CSPs) and list the specific requirements for each.
  3. Describe the requirements for personnel qualification and evaluation.
  4. Explain the increased frequencies for environmental monitoring and cleaning.

NHIA General CE Information

Abby Roth, BS, CMQ/OE

Founder

Pure Microbiology

Abby Roth, founder of Pure Microbiology, has over 18 years of experience in supporting the testing and consulting needs of the pharmaceutical, medical device, and compounding industries. Her background in pharmaceutical microbiology includes extensive knowledge of environmental monitoring. Abby served as a USP Compounding EC member during the 2015-2020 cycle. She is an involved member of the Controlled Environment Testing Association (CETA), serving on the Board of Directors, speaking at its annual meetings, and chairing committees for the revision of four CETA Application Guides. Abby has been invited to speak for state boards of pharmacy and for national organizations.

NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

 Abby Roth has no relevant financial relationships with ineligible companies to disclose.

Key:

Complete
Failed
Available
Locked
2023 Revisions to USP 797: What Home Infusion Pharmacies Need to Know
Open to download resource.
Open to download resource.
You must register to access.
Post Education Survey
8 Questions
8 Questions 2023 Revision to USP 797: What Home Infusion Pharmacies Need to Know INFUSION Article, 1.00 CE JA4008389-0000-25-002-H07-P&T & 202884451 RN&RD
You must register to access.
Required to Claim CE
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available **PHARMACISTS & PHARMACY TECHNICIANS MUST SELECT THE BLUE "CLAIM CREDIT" BUTTON & ENTER YOUR DOB IN ORDER TO RECEIVE CE CREDIT** ________________________________________________________________________________________________________________________________________________________________________ NHIA adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, panelists, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Please note that the certificates printed from this platform are invalid as proof of continuing education (CE). For official documentation of CE credits, please print a paper statement of credit from your NABP e-profile.
You must register to access.